Posted on : November 2nd 2021
Posted by : Viswanathan Chandrasekharan
Retrosynthetic analysis and planning is a widely used technique in chemical synthesis that helps deconstruct a target chemical compound progressively into simpler compounds by known methods and supports the planning of a final synthesis route to the target, based on cost, efficiency, and other parameters.
Typically, retrosynthetic analyses are carried out manually. Advancements in artificial intelligence (AI) and specifically deep learning have spawned sophisticated and automated algorithms with the potential to provide retrosynthetic analysis with broader applications and better accuracy. Retrosynthetic prediction tools can leverage up-to-date research from across the globe for assisting chemists in designing synthetic routes to novel molecules. These tools have many applications in drug discovery, medicinal chemistry, materials science, and natural product synthesis.
AI-enabled retrosynthetic planning – a roadmap to guide the synthesis of a molecular target – uses machine learning (ML) models to achieve the required results. However, the data used to train the models determine the accuracy, uniformity, and reproducibility of the predictions. Therefore, high-quality and diverse training reaction data sets are needed to optimize automated synthetic planning initiatives.
In retrosynthetic planning, the goal is to reduce the complexity of the molecular target, and it is achieved by creating diverse and accurate synthetic routes. However, machine-learning models used in retrosynthetic planning applications are only as good as the chemical structures and thousands of data points sourced from multiple sources. Data diversity is a key challenge in data-driven automatic retrosynthetic route planning. If the training data do not encompass all chemical and chemistry subspaces, the results will be limited in scope and efficiency.
For improving the predictive power of AI-enabled retrosynthesis planning, a very large corpus of chemical information accessible across patents, journals, and other scientific publications must be first curated. Subsequently, the data should be enriched, managed, and presented as integratable data for retrosynthetic analysis. In addition, this process should be ongoing and continue in tandem with machine learning to empower and enrich AI-supported retrosynthetic planning.
The challenges posed by the pandemic due to COVID-19 have accelerated digital transformation in the pharmaceutical and life sciences fields. The breakneck speed at which vaccines have been developed portends that the development of other therapeutics could also be fast-tracked in the future. Using a reliable synthesis plan from AI-driven retrosynthetic planning for the quicker and successful synthesis of target molecules could support and fast-track therapeutics development.
Straive’s data solutions suite is designed for extracting data from text, images, tables, and plots in patents, journals, and scientific publications of different formats.
Powered by our proprietary AI-enabled Straive Data Platform, our unstructured-data solutions are capable of selective data picking from tables and numerical data farming from graphs, images, and figures. Data thus extracted are enriched and validated by our in-house chemistry subject matter experts. Subsequently, the data is delivered as integratable data that can be used as training data sets for retrosynthetic planning initiatives or used by scientists and researchers to gain further insights.
Regulators want LIBOR to phased out by December 2021, banks and financial institutes must pivot to risk-free alternative rates.
We have been recognized among the “Top 20 Most Promising Big Data Solution Providers – 2020” in a recent listing by a leading global print magazine. The aforementioned list recognizes an exclusive set of solution providers with a proven track record of consistently delivering customer goals.
The COVID-19 has triggered a rush of clinical trials to discover vaccines, threatening the continuity and success of non-COVID-19 drug discovery pipelines. This guide will help you learn to mitigate these new challenges, maintain pole position, and grow your business into the future with practical strategies for decentralization.
Enterprises tend to employ data from external sources in their data strategy to convert insights into financial gain as they mature in their data journey. This external data comes in diverse forms. However, for enterprises, the most critical is public data.
There are currently no compliance mandate around ESG reporting, especially for private companies, and such reporting is voluntary. While many large companies report on ESG as part of CSR, growing awareness among investors and consumers about ESG has led to this becoming a more widespread practice.
Our solutioning team is eager to know about your challenge and how we can help.